Al-Masaeed Mahmoud, Alghawanmeh Mohammad, Al-Singlawi Ashraf, Alsababha Rawan, Alqudah Muhammad
Faculty of Health and Medicine, University of Newcastle, Callaghan 2308, Australia.
Faculty of Pharmacy, Philadelphia University, Amman 19392, Jordan.
Healthcare (Basel). 2021 May 10;9(5):557. doi: 10.3390/healthcare9050557.
: The review seeks to shed light on the administered and recommended COVID-19 treatment medications through an evaluation of their efficacy. : Data were collected from key databases, including Scopus, Medline, Google Scholar, and CINAHL. Other platforms included WHO and FDA publications. The review's literature search was guided by the WHO solidarity clinical trials for COVID-19 scope and trial-assessment parameters. : The findings indicate that the use of antiretroviral drugs as an early treatment for COVID-19 patients has been useful. It has reduced hospital time, hastened the clinical cure period, delayed and reduced the need for mechanical and invasive ventilation, and reduced mortality rates. The use of vitamins, minerals, and supplements has been linked to increased immunity and thus offering the body a fighting chance. Nevertheless, antibiotics do not correlate with improving patients' wellbeing and are highly discouraged from the developed clinical trials. : The review demonstrates the need for additional clinical trials with a randomized, extensive sample base and over a more extended period to examine the potential side effects of the medications administered. Critically, the findings underscore the need for vaccination as the only viable medication to limit the SARS-CoV-2 virus spread.
该综述旨在通过评估新冠治疗药物的疗效，阐明已应用及推荐使用的新冠治疗药物情况。数据收集自关键数据库，包括Scopus、Medline、谷歌学术和护理学与健康领域数据库（CINAHL）。其他平台包括世界卫生组织（WHO）和美国食品药品监督管理局（FDA）的出版物。该综述的文献检索以WHO针对新冠的团结临床试验范围和试验评估参数为指导。研究结果表明，使用抗逆转录病毒药物作为新冠患者的早期治疗手段是有效的。它缩短了住院时间，加快了临床治愈期，推迟并减少了机械通气和有创通气的需求，降低了死亡率。使用维生素、矿物质和补充剂与增强免疫力有关，从而为身体提供了抗争的机会。然而，抗生素与改善患者健康状况并无关联，在已开展的临床试验中强烈不建议使用。该综述表明，需要进行更多临床试验，采用随机、广泛的样本库并持续更长时间，以研究所用药物的潜在副作用。至关重要的是，研究结果强调了接种疫苗作为限制严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒传播的唯一可行药物的必要性。
